ST Pharm Co.,Ltd. (KOSDAQ:237690)
South Korea · Delayed Price · Currency is KRW 88,500
+3,800 (4.49%)
Jul 31, 2026, 3:30 PM KST
ST Pharm Financials Overview
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 346,223 | 331,681 | 273,751 | 284,992 | 249,322 | 165,642 |
Revenue Growth | 26.15% | 21.16% | -3.94% | 14.31% | 50.52% | 33.47% |
Gross Profit Gross Profit Growth | 144,089 | 132,417 | 93,605 | 109,744 | 87,182 | 55,309 |
Operating Income Operating Income Growth | 65,437 | 54,933 | 27,693 | 33,512 | 17,851 | 5,578 |
Net Income Net Income Growth | 69,011 | 54,992 | 34,712 | 19,581 | 18,000 | 3,312 |
Earnings Per Share EPS Growth | 3312.63 | 2688.35 | 1779.72 | 1041.00 | 957.00 | 177.00 |
EPS Growth | 122.53% | 51.05% | 70.96% | 8.78% | 440.68% | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Clinical Trial Contract Research Clinical Trial Contract Research Growth | 48,486 | 44,938 | 30,361 | 33,759 | 40,315 | 27,156 |
Raw Material Manufacturing Raw Material Manufacturing Growth | 304,498 | 293,178 | 244,072 | 251,559 | 209,270 | 139,139 |
Consolidation Adjustment Consolidation Adjustment Growth | -6,761 | -6,435 | -681.99 | -326.1 | -263.41 | -652.92 |
Total Total Growth | 346,223 | 331,681 | 273,751 | 284,992 | 249,322 | 165,642 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 199,090 | 90,990 | 120,924 | 90,097 | 50,201 | 93,216 |
Total Debt Total Debt Growth | 74,331 | 78,714 | 118,142 | 192,082 | 134,521 | 107,517 |
Net Cash (Debt) Net Cash Growth | 124,759 | 12,276 | 2,782 | -101,984 | -84,320 | -14,301 |
Net Cash Growth | 13599.88% | 341.27% | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | 5766.33 | 572.43 | 142.64 | -5422.17 | -4483.00 | -766.21 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 99,723 | 13,989 | 109,451 | 1,298 | 7,031 | 7,270 |
Capital Expenditures CapEx Growth | -35,257 | -47,072 | -82,806 | -43,244 | -60,479 | -51,792 |
Free Cash Flow Free Cash Flow Growth | 64,466 | -33,082 | 26,646 | -41,946 | -53,448 | -44,522 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 41.62% | 39.92% | 34.19% | 38.51% | 34.97% | 33.39% |
Operating Margin | 18.90% | 16.56% | 10.12% | 11.76% | 7.16% | 3.37% |
Pretax Margin | 21.61% | 17.70% | 15.62% | 8.19% | 7.72% | 0.76% |
Profit Margin | 19.93% | 16.58% | 12.68% | 6.87% | 7.22% | 2.00% |
FCF Margin | 18.62% | -9.97% | 9.73% | -14.72% | -21.44% | -26.88% |
| Fiscal Year | Current | FY 2025 |
|---|---|---|
| Period Ending | Aug '26 Aug 1, 2026 | Dec '25 Dec 31, 2025 |
Dividend Per Share Dividend Per Share Growth | 500.000 | 500.000 |
Dividend Per Share Growth | 0% | - |
Dividend Yield | 0.59% | 0.42% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 26.72 | 44.87 | 51.57 | 65.13 | 91.54 | 784.06 |
Forward PE | 22.98 | 39.88 | 36.22 | 37.69 | 67.19 | 133.19 |
P/FCF Ratio | 28.66 | - | 67.18 | - | - | - |
PS Ratio | 5.34 | 7.44 | 6.54 | 4.47 | 6.61 | 15.68 |